title: Effect of monophosphoryl lipid A (MPLA) on peritoneal leukocyte function.
abstract: We analyzed the in vitro effects of monophosphoryl lipid A (MPLA), a nontoxic bacterial endotoxin-derived immunomodulant, on the depressed immune functions of peritoneal lymphocytes (PLy) and macrophages (PMO) of 6 CAPD patients with relapsing bacterial peritonitis. MPLA was also tested for its capacity to stimulate the peritoneal fibroblast proliferation as determined by 3H-thymidine incorporation. In vitro incubation of PLy and PMO with escalating doses of MPLA up to 5 micrograms/ml, resulted in a dose-dependent enhancement of Gamma-Interferon (Gamma-IFN) and Interleukin-2 (IL-2) production by PLy, and Interleukin-1 (IL-1) by PMO. There was also an increase in PMO bacterial killing and membrane Fc receptor number, while no change in peritoneal fibroblast proliferation was seen with any of the MPLA concentrations tested. These results suggest that the peritoneal leukocyte abnormalities observed in some high peritonitis rate CAPD patients may be reversed, to some degree, by MPLA, without directly inducing a potentially deleterious peritoneal fibrosis.
authors.affiliation: Nephrology and Dialysis Unit, St. Paul's Hospital, Savona, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Carozzi
authors.forename: M G
authors.initials: MG
authors.lastname: Nasini
authors.forename: C
authors.initials: C
authors.lastname: Schelotto
authors.forename: P M
authors.initials: PM
authors.lastname: Caviglia
authors.forename: O
authors.initials: O
authors.lastname: Santoni
authors.forename: S
authors.initials: S
authors.lastname: Barocci
authors.forename: S
authors.initials: S
authors.lastname: Cantarella
authors.forename: F
authors.initials: F
authors.lastname: Versace
authors.forename: M
authors.initials: M
authors.lastname: Salit
authors.forename: A
authors.initials: A
authors.lastname: Cantaluppi
mesh_terms: D000328:Adult; D002455:Cell Division / Q000187:drug effects; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000473:pathology; D006801:Humans; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis; D007375:Interleukin-1 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D008050:Lipid A / Q000031:analogs & derivatives* / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008262:Macrophage Activation / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010529:Peritoneal Cavity / Q000473:pathology; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D010538:Peritonitis / Q000209:etiology / Q000276:immunology; D011961:Receptors, Fc / Q000378:metabolism; D012008:Recurrence; D013212:Staphylococcus epidermidis / Q000502:physiology
chemical_list: D007375:Interleukin-1; D007376:Interleukin-2; D008050:Lipid A; D011961:Receptors, Fc; D007371:Interferon-gamma; C048436:monophosphoryl lipid A